Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012
COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014
Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD). Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015
Safety of sputum induction (SI) in interstitial lung disease (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007
Correlation of induced sputum (IS) particles size distribution (PDS) and pulmonary function test (PFT) in asthmatics patients (A-pts) Source: Eur Respir J 2004; 24: Suppl. 48, 604s Year: 2004
The indices of body composition (IBC) consideration the changes of serum TNF-α, hormones and oxygen saturation (SO2%) in men with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases Year: 2012
The relationship between echodensitometric parameters of respiratory muscles (RM) and indices of body composition (IBC) in men with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - Morphological and functional imaging in obstructive airway disease Year: 2011
Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Concentration of NO2-, a-acid protein (AAP), tumor necrotic factor (TNF-a), in the induced sputum of patients with bronchial asthma(BA) and chronic obstructive bronchitis (COB) Source: Eur Respir J 2001; 18: Suppl. 33, 367s Year: 2001
Induced sputum (IS) angiogenic cytokines in patients with sarcoidosis (SA) Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005
Impact of host status, bacteria and antibiotic therapy on systemic inflammatory response syndrome (SIRS) development in community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Study on the relation between serum complement (C3, C4) levels and acute exacerbations in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008
Differences between local and systemic inflammatory response in patients with community acquired pneumonia (CAP) Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia Year: 2011